List of Excipients in Branded Drug EZETIMIBE AND SIMVASTATIN

« Back to Dashboard

Generic Drugs Containing EZETIMIBE AND SIMVASTATIN

Company	Ingredient	NDC	Excipient
NORTHSTAR RX LLC	ezetimibe and simvastatin	16714-778	BUTYLATED HYDROXYANISOLE
NORTHSTAR RX LLC	ezetimibe and simvastatin	16714-778	CELLULOSE, MICROCRYSTALLINE
NORTHSTAR RX LLC	ezetimibe and simvastatin	16714-778	CITRIC ACID MONOHYDRATE
NORTHSTAR RX LLC	ezetimibe and simvastatin	16714-778	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in EZETIMIBE AND SIMVASTATIN?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
3	ASCORBIC ACID
1	BHA
17	BUTYLATED HYDROXYANISOLE

Ezetimibe and Simvastatin Excipient Strategy and Commercial Opportunities

Last updated: October 5, 2026

Ezetimibe/simvastatin is a mature, immediate-release fixed-dose combination with extensive generic competition and no meaningful U.S. regulatory exclusivity remaining. Commercial opportunity is concentrated in manufacturing efficiency, reliable dissolution, global registration, differentiated packaging, and supply contracts rather than in novel active-ingredient protection. The core formulation challenge is combining two poorly water-soluble drugs with different physicochemical properties in a stable, bioequivalent tablet.

What is the commercial status of ezetimibe and simvastatin?

Ezetimibe/simvastatin was commercialized by Merck under the Vytorin brand. The product combines intestinal cholesterol-absorption inhibition from ezetimibe with HMG-CoA reductase inhibition from simvastatin.

Attribute	Product profile
Active ingredients	Ezetimibe and simvastatin
Original brand	Vytorin
U.S. dosage strengths	10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg
Dosage form	Immediate-release film-coated tablet
FDA application	NDA 021687
Administration	Once daily, with or without food
Main indications	Primary hyperlipidemia, homozygous familial hypercholesterolemia, mixed hyperlipidemia, cardiovascular-risk reduction in selected patients
Regulatory pathway for competitors	Abbreviated New Drug Application, or ANDA
Current U.S. exclusivity position	No meaningful remaining brand exclusivity
Principal commercial competitors	Generic ezetimibe/simvastatin, generic ezetimibe, generic statins, high-intensity atorvastatin and rosuvastatin

The 10/80-mg strength is commercially and clinically constrained because of simvastatin-associated myopathy and rhabdomyolysis risk. FDA restricts initiation at this strength and generally limits its use to patients who have taken simvastatin 80 mg for at least 12 months without muscle toxicity and who require continued LDL-cholesterol reduction at that dose [1].

The market is therefore centered on the 10/10-, 10/20-, and 10/40-mg strengths. The 10/40-mg tablet is likely to have the broadest commercial relevance because it combines a standard ezetimibe dose with a moderate-to-high simvastatin dose without the special restrictions associated with 80 mg.

What excipient strategy is appropriate for ezetimibe/simvastatin tablets?

The optimal strategy is a conventional, low-cost immediate-release tablet using excipients that support wet granulation or optimized direct compression, rapid disintegration, reproducible dissolution, and protection from moisture and oxidation.

The formulation should treat the two active ingredients as separate development problems before combining them in the final dosage form.

Ezetimibe formulation considerations

Ezetimibe has low aqueous solubility and is sensitive to formulation-dependent dissolution performance. Its commercial formulation must maintain consistent exposure despite limited intrinsic solubility.

Useful excipient functions include:

• Wetting and dissolution enhancement
• Improved powder flow and content uniformity
• Rapid tablet disintegration
• Protection against moisture-related degradation
• Prevention of segregation between ezetimibe and the larger quantity of tablet excipients

Potential excipients include microcrystalline cellulose, lactose monohydrate, crospovidone, croscarmellose sodium, povidone, sodium lauryl sulfate, and low levels of colloidal silicon dioxide. Surfactants can improve wetting, but their concentration must be controlled because excessive surfactant can alter dissolution profiles, create processing problems, or affect stability.

Simvastatin formulation considerations

Simvastatin is a lipophilic lactone with limited water solubility. It can undergo hydrolysis to simvastatin acid and is vulnerable to degradation under unsuitable moisture, temperature, or pH conditions.

The formulation should prioritize:

• Low-moisture processing
• Controlled exposure to alkaline conditions
• Protection from heat and light
• Uniform distribution at low drug loading
• Consistent dissolution across manufacturing sites
• Compatibility with the selected binder and disintegrant system

Simvastatin is present at relatively low dose levels compared with the total tablet mass. Content uniformity and segregation control are therefore important, especially for high-throughput direct-compression processes.

Recommended excipient platform

A conventional platform may contain:

Function	Candidate excipients	Strategic purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol	Tablet mass, compressibility, powder flow
Binder	Povidone, hydroxypropyl cellulose	Granule strength and content uniformity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Rapid tablet breakup
Wetting agent	Sodium lauryl sulfate or another low-level surfactant	Improved wetting of hydrophobic drug particles
Glidant	Colloidal silicon dioxide	Flow and die filling
Lubricant	Magnesium stearate	Ejection and tooling protection
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, approved colorants	Identification, handling, light and moisture protection

The original Vytorin formulation uses a conventional excipient architecture that includes lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, sodium lauryl sulfate, and film-coating components [2]. A generic manufacturer does not need to reproduce the brand formulation, but the product must satisfy quality, bioequivalence, and applicable inactive-ingredient requirements.

Which manufacturing process is best for ezetimibe/simvastatin?

Wet granulation is usually the lower-risk development route when the formulation has poor flow, segregation risk, or low-dose uniformity problems. It can improve distribution of simvastatin and ezetimibe throughout the tablet blend, but it introduces water exposure and a drying step that may affect simvastatin stability.

Direct compression offers lower cost, fewer unit operations, and easier scale-up. It is commercially attractive when the active ingredients have adequate flow and the formulation can maintain content uniformity. The principal risks are segregation, poor blend homogeneity, sticking, and dissolution variability.

Dry granulation is a possible compromise for a moisture-sensitive process. Roller compaction can reduce water exposure while improving flow, although it may increase tablet hardness and slow disintegration if the ribbon is overcompacted.

Process	Cost	Main advantage	Main risk
Direct compression	Lowest	Simple process and high throughput	Segregation and low-dose uniformity
Wet granulation	Moderate	Strong content uniformity and robust compression	Moisture and thermal exposure
Dry granulation	Moderate	Lower moisture exposure than wet granulation	Hard granules and slower dissolution
Separate-layer tablet	Highest	Physical separation of active ingredients	More complex equipment and validation

A conventional single-layer tablet is generally the most commercially efficient design. A bilayer tablet may be useful where compatibility, dissolution control, or segregation cannot be managed in a single blend, but it adds equipment, process validation, and manufacturing cost without necessarily creating patent protection.

What formulations are protected by patents?

The principal active-ingredient and combination-product patent barriers for ezetimibe/simvastatin have expired or reached the end of their relevant terms in the United States. The original ezetimibe and combination patents were filed in the 1990s and early 2000s, placing them outside the normal life of a current U.S. patent portfolio.

Potentially relevant historical patent categories included:

• Ezetimibe composition-of-matter patents
• Simvastatin composition and process patents
• Combination-treatment patents
• Solid oral dosage-form patents
• Manufacturing and purification patents
• Method-of-use patents for lipid disorders and cardiovascular risk

Current formulation development should not assume that a routine use of lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, or a standard film coat creates enforceable exclusivity. Those excipients are widely used and generally do not provide commercial patent differentiation by themselves.

A new patent opportunity would require a technically specific claim, such as:

• A novel amorphous or crystalline form
• A defined particle-size distribution
• A controlled-release or modified-release system
• A stability-enhancing composition with demonstrated superiority
• A manufacturing process that produces a distinct solid-state form
• A clinically meaningful pharmacokinetic or tolerability advantage
• A specialized dosage form for a defined patient population

For a conventional immediate-release generic, patents are more likely to protect a narrow process or formulation feature than the commercial product as a whole.

What is the Orange Book status of ezetimibe/simvastatin?

The FDA Orange Book identifies approved drug products, reference listed drugs, patents, and regulatory exclusivity. Vytorin and generic ezetimibe/simvastatin products are evaluated through the FDA’s approved-drug and patent-listing databases [3].

The commercial implications are:

1. The branded product no longer has a practical market-exclusivity barrier based on the original active-ingredient patents.
2. Generic applicants can use the ANDA pathway if they demonstrate pharmaceutical equivalence and bioequivalence.
3. Any remaining listed patent would need to be reviewed by product, strength, and patent status.
4. A Paragraph IV certification could trigger litigation, but the historic patent age makes a new blocking patent event unlikely for a conventional generic product.
5. Any current commercial barrier is more likely to arise from manufacturing capacity, customer contracts, supply reliability, or regulatory deficiencies.

When did ezetimibe/simvastatin lose exclusivity?

The original U.S. exclusivity period ended years ago. Ezetimibe’s original composition-of-matter protection and associated combination patents were filed sufficiently early that they no longer provide a durable barrier to generic development.

The relevant timing sequence was:

Milestone	Commercial effect
Original Vytorin approval	Established the reference listed drug
Expiration of core ezetimibe and combination patents	Opened the product to generic competition
FDA approval of ANDA products	Shifted volume from branded to generic supply
Decline of branded share	Reduced value of conventional formulation patents
Mature generic market	Increased importance of price, availability, and regulatory execution

Any precise patent-expiration analysis should be performed against the current Orange Book record because patent listings, pediatric extensions, terminal disclaimers, and product-specific entries can differ. The underlying commercial conclusion remains unchanged: a conventional ezetimibe/simvastatin tablet is a mature generic opportunity rather than a protected innovative-product opportunity.

Which companies are challenging or supplying ezetimibe/simvastatin?

Generic supply has historically included large multinational manufacturers and specialty generic companies. Potential suppliers include companies with established cardiovascular portfolios, U.S. ANDA infrastructure, and access to low-cost API and finished-dose manufacturing.

The competitive set should be evaluated across four dimensions:

Competitive factor	Commercial impact
ANDA approval status	Determines immediate ability to supply the U.S. market
Number of approved strengths	Broad strength coverage improves contracting position
FDA inspection history	Affects continuity of supply and customer confidence
API source and vertical integration	Influences cost and resilience
Authorized-generic or brand relationships	Can affect channel access
Contract manufacturing capacity	Determines launch speed and inventory flexibility

A generic entrant that launches only 10/10 mg may face limited differentiation. A complete portfolio covering 10/10, 10/20, and 10/40 mg has stronger value for wholesalers, health systems, and pharmacy benefit managers. The 10/80-mg strength should be approached selectively because of its restricted clinical use.

What generic launch risks exist?

The principal risks are regulatory and operational rather than patent-based.

Bioequivalence risk

Both active ingredients must meet FDA bioequivalence requirements against the reference product. Poor dissolution of either component can produce unacceptable exposure variability. The company should establish discriminatory dissolution methods early and correlate in vitro performance with pharmacokinetic results where possible [4].

Content-uniformity risk

Simvastatin is a low-dose component relative to the tablet mass. Segregation during blending, transfer, or hopper discharge can cause assay and content-uniformity failures.

Stability risk

The formulation should be tested under accelerated and long-term conditions with attention to:

• Simvastatin lactone and hydrolysis products
• Ezetimibe degradation products
• Moisture uptake
• Color change
• Dissolution drift
• Coating integrity
• Container-closure performance

Scale-up risk

A formulation that performs in a laboratory blender may fail at commercial scale because of blend-time changes, shear differences, feeder variability, or tablet compression-speed effects.

Clinical and labeling risk

The product label must reflect simvastatin safety restrictions, drug interactions, contraindications, and dose limitations. FDA labeling identifies important interactions involving strong CYP3A4 inhibitors and other drugs that increase myopathy risk [1].

How can excipients create commercial opportunity?

Excipients create commercial value when they reduce cost, improve manufacturing robustness, or support a differentiated product claim. They rarely create value merely because they are new.

Cost-reduction opportunity

A manufacturer can reduce cost through:

• Direct compression
• Lower coating weight
• Fewer excipient grades
• Common excipient platforms across strengths
• High-speed compression
• Regional sourcing of qualified excipients
• Reduced solvent or water use
• Standardized packaging components

The formulation should be designed so that all strengths use the same qualitative excipient system. A common platform reduces validation burden and allows strength changes through active-to-filler ratio adjustments.

Stability opportunity

A low-moisture formulation and high-barrier blister or bottle can reduce degradation. Aluminum-aluminum blister packaging may provide stronger protection than standard high-density polyethylene bottles but can raise packaging cost. The optimal choice depends on climate zone, target market, shelf life, and distribution conditions.

Patient-adherence opportunity

The fixed-dose combination itself supports adherence by reducing pill burden. A smaller tablet, clear strength identification, calendar packaging, and color differentiation may improve usability without requiring a new active pharmaceutical ingredient.

Global-market opportunity

The product is attractive in markets where:

• Combination cardiovascular therapy is reimbursed
• Ezetimibe is widely available
• Generic substitution is permitted
• Simvastatin remains clinically accepted
• Local manufacturers seek cardiovascular portfolio expansion

Regulatory requirements differ across the United States, European Union, Canada, Japan, and emerging markets. A global program should use a core formulation but allow for local excipient restrictions, dissolution criteria, packaging expectations, and reference-product requirements.

What licensing deals are relevant?

Licensing value is limited for a standard generic because the core intellectual property has expired. Transactions are more likely to involve:

• ANDA or marketing-authorization rights
• Regional distribution rights
• Contract manufacturing
• Technology transfer
• API supply agreements
• Authorized-generic arrangements
• Portfolio bundling with ezetimibe, atorvastatin, rosuvastatin, or other cardiovascular products

A formulation license becomes more defensible if it includes a protected solid-state form, a validated manufacturing process, a differentiated delivery system, or a market-specific regulatory package. A basic excipient recipe without patent protection is more suitable for internal development or contract manufacturing than for a high-value license.

How strong is the patent estate for ezetimibe/simvastatin?

The patent estate is weak for a conventional immediate-release generic. The active ingredients are mature, the principal patent terms have expired, and routine excipient combinations are difficult to protect broadly.

Patent category	Current strategic strength
Ezetimibe composition	Expired or commercially nonblocking
Simvastatin composition	Expired
Basic combination tablet	Weak
Conventional excipient system	Very weak
Novel solid-state form	Potentially moderate
Modified-release formulation	Potentially moderate to strong if clinically differentiated
Manufacturing process	Narrow but potentially useful
Method of use	Limited value for ANDA market access
Packaging configuration	Usually weak unless tied to a technical stability result

A new entrant should avoid relying on patent protection as the primary investment thesis. The stronger thesis is efficient production plus reliable regulatory execution.

What patent litigation and Paragraph IV risks affect the product?

Historical Paragraph IV activity was relevant when core ezetimibe and combination patents remained in force. For a new conventional generic entrant, the probability of a commercially material Paragraph IV dispute is lower because the major patent barriers have expired.

Potential litigation could still arise from:

• A later-filed solid-state patent
• A polymorph or particle-size patent
• A narrow formulation patent
• A manufacturing-process patent
• A patent covering a specific patient population
• Alleged infringement involving an ANDA product

The presence of a patent listing does not automatically establish a blocking right. The patent’s claim scope, expiration, certification requirement, enforceability, and relevance to the proposed formulation must be reviewed separately under the current Orange Book record and applicable patent databases [3, 5].

How does ezetimibe/simvastatin compare with competing lipid products?

Ezetimibe/simvastatin faces competition from both other statins and single-agent ezetimibe.

Product	Competitive position
Ezetimibe/simvastatin	Low-cost combination; reduced pill burden
Ezetimibe alone	Useful when statin intensity is limited or additional LDL lowering is needed
Atorvastatin	Strong generic availability and broad dose range
Rosuvastatin	High-potency generic statin with strong prescribing position
Simvastatin alone	Low-cost but generally less attractive than high-intensity alternatives
PCSK9 inhibitors	Higher potency and price; used mainly in selected high-risk patients
Bempedoic acid combinations	Alternative for statin-intolerant or high-risk patients

The combination’s commercial disadvantage is that simvastatin has been displaced in some treatment pathways by atorvastatin and rosuvastatin. Its advantage is price, familiarity, and the convenience of adding ezetimibe without prescribing two products.

What revenue exposure and launch scenarios are realistic?

Separate current Vytorin revenue is not a reliable indicator of generic opportunity because branded sales are affected by generic substitution, channel discounts, portfolio reporting, and geographic aggregation. The relevant metrics are prescription volume, average generic selling price, payer concentration, and expected share after launch.

Three launch scenarios are commercially realistic:

Scenario	Characteristics	Expected outcome
Price-led launch	Standard formulation, multiple strengths, aggressive wholesaler pricing	Rapid volume but low margin
Supply-reliability launch	Strong inventory, redundant API sources, stable quality record	Better contracting position and durable share
Differentiated formulation launch	Protected formulation or packaging advantage	Higher margin but greater development and legal cost

The most attractive base case is a reliable, low-cost product covering 10/10, 10/20, and 10/40 mg, supported by a common excipient platform and high-barrier packaging where stability data justify it.

Key Takeaways

• Ezetimibe/simvastatin is a mature generic fixed-dose combination with no meaningful remaining U.S. exclusivity barrier.
• The main formulation challenge is combining two poorly soluble drugs while controlling dissolution, content uniformity, and simvastatin stability.
• Microcrystalline cellulose, lactose, croscarmellose sodium, povidone, magnesium stearate, and a low-level wetting agent provide a practical starting platform.
• Direct compression offers the lowest cost, while wet or dry granulation may provide greater manufacturing robustness.
• The 10/10-, 10/20-, and 10/40-mg strengths are the most commercially relevant; 10/80 mg has restricted clinical use.
• Patent value is limited for a routine immediate-release tablet. New IP would need to cover a specific solid-state, process, release, stability, or clinical-performance advantage.
• The strongest commercial opportunities are supply reliability, multi-strength coverage, efficient excipient sourcing, global registration, and payer-oriented pricing.
• Paragraph IV and litigation risk is lower than in the original generic-entry period, but current Orange Book listings and later formulation patents still require product-specific review.
• A successful launch depends more on cost control, bioequivalence, stability, and manufacturing resilience than on novel excipient selection.

Frequently Asked Questions

Is ezetimibe/simvastatin still protected by patents?

The original composition and combination patent barriers are no longer a practical obstacle to conventional generic development in the United States. Current Orange Book records should be reviewed for any later product-specific listings.

Which strength of ezetimibe/simvastatin has the best commercial potential?

The 10/40-mg strength is generally the strongest commercial candidate because it provides a meaningful LDL-lowering combination without the major clinical restrictions associated with simvastatin 80 mg.

Can a new excipient combination receive patent protection?

Yes, but broad protection is unlikely for routine excipients. Patentability is stronger when the formulation delivers a demonstrated technical result, such as improved stability, a distinct solid-state form, faster dissolution, or a clinically relevant pharmacokinetic advantage.

Is a bilayer tablet commercially attractive?

Usually only when single-layer processing cannot control compatibility, segregation, or dissolution. A bilayer tablet increases manufacturing complexity and cost and does not automatically provide market exclusivity.

What is the main regulatory risk for a generic product?

The main risk is failure to match the reference product’s exposure and dissolution performance for both active ingredients. Stability, content uniformity, manufacturing scale-up, and labeling compliance are the next major risks.

References

1. U.S. Food and Drug Administration. (2022). Vytorin (ezetimibe and simvastatin) prescribing information.
2. Merck & Co., Inc. (2022). Vytorin product label and inactive ingredients.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2021). Bioequivalence studies with pharmacokinetic endpoints for generic drug products.
5. United States Patent and Trademark Office. (2025). Patent Center and patent term resources.